消化

订阅

MedSci主页 / 所有栏目 / 消化

JNCI：饮食血糖负荷增加III期结肠癌患者肿瘤复发风险

2012-11-26 MedSci JNCI

JNCI血糖结肠癌肿瘤
关注

    在结肠癌患者中，血糖负荷对其生存情况影响目前还知之甚少。为了解决上述问题，Jeffrey A. Meyerhardt等进行了相关研究，其研究结果发表在JNCI 11月最新的在线期刊上。    这个研究是前瞻性、观察性研究，研究纳入了1011名III期结肠癌患者，要求这些患者记录其在接受辅助化疗期间和之后6个月的饮食摄入情况。研究者

    在结肠癌患者中，血糖负荷对其生存情况影响目前还知之甚少。为了解决上述问题，Jeffrey A. Meyerhardt等进行了相关研究，其研究结果发表在JNCI 11月最新的在线期刊上。
    这个研究是前瞻性、观察性研究，研究纳入了1011名III期结肠癌患者，要求这些患者记录其在接受辅助化疗期间和之后6个月的饮食摄入情况。研究者调查了血糖负荷、血糖指数、果糖和碳水化合物摄入对肿瘤复发和死亡率的影响，研究者采用Cox风险比例回归进行分析。
    研究结果显示，与低四分位的患者相比，处于高四分位的饮食血糖负荷的III期结肠癌患者其无疾病生存率的调整后危险比为1.79。血糖负荷增高会导致复发率增高和总体生存率降低。这种联系显著受到质量指数（BMI）的影响。如果患者的BMI< 25 kg/m2，那么血糖负荷与无病生存期的联系消失，而在超重或肥胖的患者中，血糖负荷增高与无病生存期减低相关。碳水化合物摄入增多会导致无病生存期降低、无复发生存期降低以及总体生存期降低。
    研究结果显示，饮食高血糖负荷和总体碳水化合物摄入会显著增加III期结肠癌患者的复发风险和死亡风险。这些发现支持能量平衡与结肠癌进展相关，可能会改善患者的生存预后。
原始来源：

Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS.Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. J Natl Cancer Inst. 2012 Nov 21;104(22):1702-11. doi: 10.1093/jnci/djs399. Epub 2012 Nov 7.


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915769, encodeId=e8601915e69c7, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Dec 27 22:11:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705577, encodeId=46891e05577ec, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Tue Feb 26 15:11:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041012, encodeId=250320410125d, content=<a href='/topic/show?id=6ef4898581e' target=_blank style='color:#2F92EE;'>#血糖负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89858, encryptionId=6ef4898581e, topicName=血糖负荷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Jul 12 09:11:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905427, encodeId=accc190542ec8, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Jan 09 12:11:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933631, encodeId=5b5c193363184, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Feb 19 17:11:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594324, encodeId=e9f4159432421, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 28 06:11:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2012-12-27 juliusluan78

    #III#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1915769, encodeId=e8601915e69c7, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Dec 27 22:11:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705577, encodeId=46891e05577ec, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Tue Feb 26 15:11:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041012, encodeId=250320410125d, content=<a href='/topic/show?id=6ef4898581e' target=_blank style='color:#2F92EE;'>#血糖负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89858, encryptionId=6ef4898581e, topicName=血糖负荷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Jul 12 09:11:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905427, encodeId=accc190542ec8, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Jan 09 12:11:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933631, encodeId=5b5c193363184, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Feb 19 17:11:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594324, encodeId=e9f4159432421, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 28 06:11:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2013-02-26 AspirantSuo

    #肿瘤复发#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1915769, encodeId=e8601915e69c7, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Dec 27 22:11:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705577, encodeId=46891e05577ec, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Tue Feb 26 15:11:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041012, encodeId=250320410125d, content=<a href='/topic/show?id=6ef4898581e' target=_blank style='color:#2F92EE;'>#血糖负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89858, encryptionId=6ef4898581e, topicName=血糖负荷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Jul 12 09:11:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905427, encodeId=accc190542ec8, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Jan 09 12:11:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933631, encodeId=5b5c193363184, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Feb 19 17:11:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594324, encodeId=e9f4159432421, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 28 06:11:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2013-07-12 heli0118

    #血糖负荷#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1915769, encodeId=e8601915e69c7, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Dec 27 22:11:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705577, encodeId=46891e05577ec, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Tue Feb 26 15:11:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041012, encodeId=250320410125d, content=<a href='/topic/show?id=6ef4898581e' target=_blank style='color:#2F92EE;'>#血糖负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89858, encryptionId=6ef4898581e, topicName=血糖负荷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Jul 12 09:11:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905427, encodeId=accc190542ec8, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Jan 09 12:11:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933631, encodeId=5b5c193363184, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Feb 19 17:11:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594324, encodeId=e9f4159432421, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 28 06:11:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2013-01-09 wushaoling

    #复发风险#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1915769, encodeId=e8601915e69c7, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Dec 27 22:11:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705577, encodeId=46891e05577ec, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Tue Feb 26 15:11:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041012, encodeId=250320410125d, content=<a href='/topic/show?id=6ef4898581e' target=_blank style='color:#2F92EE;'>#血糖负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89858, encryptionId=6ef4898581e, topicName=血糖负荷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Jul 12 09:11:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905427, encodeId=accc190542ec8, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Jan 09 12:11:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933631, encodeId=5b5c193363184, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Feb 19 17:11:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594324, encodeId=e9f4159432421, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 28 06:11:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2013-02-19 lanyan20020086

    #NCI#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1915769, encodeId=e8601915e69c7, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Dec 27 22:11:00 CST 2012, time=2012-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705577, encodeId=46891e05577ec, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Tue Feb 26 15:11:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041012, encodeId=250320410125d, content=<a href='/topic/show?id=6ef4898581e' target=_blank style='color:#2F92EE;'>#血糖负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89858, encryptionId=6ef4898581e, topicName=血糖负荷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Jul 12 09:11:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905427, encodeId=accc190542ec8, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Jan 09 12:11:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933631, encodeId=5b5c193363184, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Tue Feb 19 17:11:00 CST 2013, time=2013-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594324, encodeId=e9f4159432421, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Nov 28 06:11:00 CST 2012, time=2012-11-28, status=1, ipAttribution=)]
    2012-11-28 智智灵药

    #III期#

    0